C.M. Bidwell & Associates’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$290K Buy
1,487
+194
+15% +$40.2K 0.12% 112
2026
Q1
$290K Sell
1,293
-6
-0.5% -$1.5K 0.14% 92
2025
Q4
$313K Sell
1,299
-46
-3% -$11.8K 0.15% 87
2025
Q3
$368K Sell
1,345
-105
-7% -$28.7K 0.18% 77
2025
Q2
$374K Sell
1,450
-76
-5% -$18.1K 0.19% 78
2025
Q1
$342K Buy
1,526
+112
+8% +$26.1K 0.21% 83
2024
Q4
$323K Sell
1,414
-23
-2% -$5.54K 0.2% 88
2024
Q3
$351K Sell
1,437
-40
-3% -$8.94K 0.21% 77
2024
Q2
$283K Sell
1,477
-6
-0.4% -$1.22K 0.19% 87
2024
Q1
$294K Buy
+1,483
New +$272K 0.2% 92
2020
Q2
Sell
-2,177
Closed -$321K 450
2020
Q1
$321K Buy
+2,177
New +$347K 0.34% 77
2019
Q4
Sell
-2,915
Closed -$394K 445
2019
Q3
$394K Sell
2,915
-110
-4% -$14.4K 0.39% 72
2019
Q2
$369K Buy
+3,025
New +$335K 0.37% 89
2017
Q2
Sell
-3,935
Closed -$283K 367
2017
Q1
$283K Buy
+3,935
New +$272K 0.06% 127
2016
Q2
Sell
-3,290
Closed -$190K 307
2016
Q1
$190K Sell
3,290
-35
-1% -$1.98K 0.05% 170
2015
Q4
$179K Buy
+3,325
New +$187K 0.04% 168

Other funds holding RMD

C.M. Bidwell & Associates's RMD Position: Q2 2026 in Review

C.M. Bidwell & Associates increased its ResMed (RMD) stake by 15% in Q2 2026, buying an estimated $40.2K and bringing the position to 1,487 shares worth $290K. The position accounts for 0.12% of the portfolio, ranked #112.

C.M. Bidwell & Associates first reported a position in RMD in Q4 2015 and has held it in 16 quarters since. The position peaked at $394K in Q3 2019. 888 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • C.M. Bidwell & Associates held 1,487 shares of ResMed worth $290K as of Q2 2026.
  • C.M. Bidwell & Associates bought 194 ResMed shares in Q2 2026, an estimated $40.2K.
  • ResMed made up 0.12% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #112 holding.
  • C.M. Bidwell & Associates first reported a position in ResMed in Q4 2015 and has held it in 16 quarters since.
  • C.M. Bidwell & Associates's ResMed position peaked at $394K in Q3 2019.
  • 888 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.